在患有类风湿性关节炎 (RA) 的成人中使用 Certolizumab Pegol 的指定患者计划
在参加开放标签研究 C87015、C87028 和 C87051 的患有类风湿性关节炎 (RA) 的成人中使用 Certolizumab Pegol 的指定患者计划
The objective of this Named Patient Program (NPP) is to provide continued availability of Certolizumab Pegol (CZP) to adult Rheumatoid Arthritis (RA) patients who participated in the open label studies C87015 (CDP870 015), C87028 (CDP870-028) and C87051 (CDP870-051). Physicians may use the option to continue offering patients CZP treatment or to transition patients off CZP to a standard care regimen.
研究概览
详细说明
The Expanded Access program was not conducted and is not intended to be conducted in the United States.
研究类型
扩展访问类型
- 个体患者
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Has/will complete(d) one of the Certolizumab Pegol (CZP) open-label studies (C87015, C87028, C87051)
- Is currently taking CZP (last dose within the last 6 weeks for subjects from C87015, and within the last 4 weeks for subjects from C87028 or C87051)
- Is informed of the details of this Named Patient Program (NPP), is given ample time and opportunity to ask questions in order to consider his/her participation in this NPP and has provided verbal consent to participate, and, if applicable according to local regulations, has given his/her written informed consent for participation
Exclusion Criteria:
-
Has been treated with any experimental biological or nonbiological therapy other than CZP within 5 plasma half-lives
-
Current safety concerns for continuing an CZP therapy related to prior biologic therapy (eg, insufficient wash out period, unresolved adverse events, unresolved recovery of peripheral B-cell/lymphocyte levels following therapy with B-cell depleters)
-
Has received live vaccinations including, but not limited to, oral polio, herpes zoster, measles-mumps-rubella (MMR) or nasal influenza within the last 8 weeks or has planned live immunizations during the planned period of administration of CZP
-
Serious or life-threatening infection within the last 6 months, including any herpes zoster infection, and/or any signs of current or recent infection
-
Active or latent tuberculosis (TB): if one or more of the 3 criteria is positive for evidence of TB infection:
- A medical history of or current active tuberculosis (TB)
- A recent (<6 months) chest X-ray with signs consistent with TB infection
- A recent (<6 months) positive purified protein derivative (PPD) skin test (defined as induration or 5 mm or more) and/or an indeterminate or positive QuantiFERON-TB Gold or Elispot test.
Patients must be monitored at least annually for active and latent TB by both 1) a chest X-ray read by a pulmonologist or radiologist and 2) a PPD skin test and/or Elispot/ QuantiFERON TB Gold test.
- Concurrent known acute or chronic viral hepatitis B or C infection
- Concurrent known human immunodeficiency virus (HIV) infection
- Concurrent malignancy or a history of malignant disease
- History of a lymphoproliferative disorder or any signs or symptoms suggestive of this disease
- History of, or suspected or confirmed active demyelinating disease of the central nervous system
- History of or concurrent New York Heart Association (NYHA) Class III/IV heart failure
- Current or recent history of severe, progressive, uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease
学习计划
研究是如何设计的?
合作者和调查者
调查人员
- 研究主任:UCB Cares、001 844 599 2273 (UCB)
研究记录日期
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.